NPT 2042 / NeuroPro Therap - LARVOL DELTA

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042 (clinicaltrials.gov) - P1 | N=8 | Recruiting | Sponsor: NeuroPro Therapeutics, Inc.

New P1 trial • Alzheimer's Disease • CNS Disorders • Epilepsy

A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042 (clinicaltrials.gov) - P1 | N=5 | Completed | Sponsor: NeuroPro Therapeutics, Inc. | Recruiting ➔ Completed

Trial completion • CNS Disorders • Epilepsy

A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures (clinicaltrials.gov) - P2 | N=10 | Recruiting | Sponsor: NeuroPro Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Absence Seizure Disorder • CNS Disorders • Epilepsy

A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures (clinicaltrials.gov) - P2 | N=10 | Not yet recruiting | Sponsor: NeuroPro Therapeutics, Inc.

New P2 trial • Absence Seizure Disorder • CNS Disorders • Epilepsy

A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042 (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: NeuroPro Therapeutics, Inc. | Trial completion date: Dec 2024 ➔ Jul 2025 | Trial primary completion date: Nov 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • CNS Disorders • Epilepsy

A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042 (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: NeuroPro Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Epilepsy

A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042 (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: NeuroPro Therapeutics, Inc.

New P1 trial • CNS Disorders • Epilepsy

Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: NeuroPro Therapeutics, Inc. | Recruiting ➔ Completed

Trial completion • Alzheimer's Disease • CNS Disorders • Epilepsy

Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: NeuroPro Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders • Epilepsy

Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: NeuroPro Therapeutics, Inc.

New P1 trial • Alzheimer's Disease • CNS Disorders • Epilepsy